Prognosis of advanced stage non-small-cell lung cancer patients receiving chemotherapy: adenocarcinoma versus squamous cell carcinoma

被引:3
作者
Soetandyo, Noorwati [1 ]
Hanafi, Arif Riswahyudi [2 ]
Agustini, Sri [1 ]
Sinulingga, Dian Triana [3 ]
机构
[1] Dharmais Natl Canc Ctr Hosp, Dept Hematol & Med Oncol, Jakarta, Indonesia
[2] Dharmais Natl Canc Ctr Hosp, Dept Pulmonol, Jakarta, Indonesia
[3] Dharmais Natl Canc Ctr Hosp, Jakarta, Indonesia
关键词
chemotherapy; histology; lung cancer; prognosis; BODY-MASS INDEX; SURVIVAL; EFFICACY; MORTALITY; OUTCOMES; SMOKING;
D O I
10.13181/mji.oa.203787
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND In Indonesia, lung cancer is one of the most prevalent solid cancer with the highest mortality rate. However, studies to identify prognostic factors associated with mortality are lacking. Thus, this study was aimed to determine the association of histological subtypes and prognosis of advanced stage non-small-cell lung cancer (NSCLC) patients receiving chemotherapy. METHODS This study focused on a retrospective cohort consisting of 60 patients with advanced stage NSCLC and treated with chemotherapy. Patients with NSCLC stage IIIB or stage IV, age >= 18 years, and good performance status were recruited. The outcomes were one-year mortality and treatment response. Gender, age, body mass index, staging, and performance status were evaluated. Chi-square and Fisher's exact tests were used. RESULTS Two common histological subtypes, adenocarcinoma (68.3%) and squamous cell carcinoma (31.7%), were observed among all subjects. Four patients (6.7%) died during one-year observation period. Mortality rate was higher in squamous cell carcinoma (10.5%) patients than in adenocarcinoma (4.9%). Underweight patients had higher risk of death (relative risk [RR] = 1.09, 95% confidence interval [CI] = 1.00-1.19) and disease progression (RR = 1.30, 95% CI = 1.12-1.51). In adenocarcinoma, metastasis was a risk for progressive disease (RR = 1.35, 95% CI = 1.09-1.66). In squamous cell carcinoma, men had a lower risk of disease progression (RR = 0.11, 95% CI = 0.03-0.41). CONCLUSIONS Squamous cell carcinoma had comparable one-year mortality and disease progression rate with adenocarcinoma type in advanced stage NSCLC. However, underweight patients had a higher risk of mortality and disease progression.
引用
收藏
页码:26 / 31
页数:6
相关论文
共 50 条
[31]   Association of polymorphisms at HORMAD2 and prognosis in advanced non-small-cell lung cancer patients [J].
Zhang, Kai ;
Tang, Shaowen ;
Cao, Songyu ;
Hu, Lingmin ;
Pan, Yun ;
Ma, Hongxia ;
Guo, Xuejiang ;
Wu, Shuangshuang ;
Shen, Hongbing ;
Hu, Zhibin .
CANCER EPIDEMIOLOGY, 2014, 38 (04) :414-418
[32]   Chemotherapy of elderly patients with non-small-cell lung cancer [J].
Kloke, O .
ZEITSCHRIFT FUR GERONTOLOGIE UND GERIATRIE, 2001, 34 (04) :277-279
[33]   Adenocarcinoma Contains More Immune Tolerance Regulatory T-cell Lymphocytes (Versus Squamous Carcinoma) in Non-small-Cell Lung Cancer [J].
Black, Candice C. ;
Turk, Mary Jo ;
Dragnev, Konstantin ;
Rigas, James R. .
LUNG, 2013, 191 (03) :265-270
[34]   Adenocarcinoma Contains More Immune Tolerance Regulatory T-cell Lymphocytes (Versus Squamous Carcinoma) in Non-small-Cell Lung Cancer [J].
Candice C. Black ;
Mary Jo Turk ;
Konstantin Dragnev ;
James R. Rigas .
Lung, 2013, 191 :265-270
[35]   Association of Chemotherapy-induced Leucopenia with Treatment Outcomes in Advanced Non-small-cell lung Cancer Cases Receiving the NP Regimen [J].
Huang, Cheng-Suo ;
Liu, Lin ;
Liu, Jie ;
Chen, Zhen ;
Guo, Jun ;
Li, Chang-Zheng ;
Zhou, Deng-Guang ;
Wang, Zhe-Hai .
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2012, 13 (09) :4481-4485
[36]   Serum cathepsin K and cystatin C concentration in patients with advanced non-small-cell lung cancer during chemotherapy [J].
Naumnik, Wojciech ;
Niklinska, Wieslawa ;
Ossolinska, Maria ;
Chyczewska, Elzbieta .
FOLIA HISTOCHEMICA ET CYTOBIOLOGICA, 2009, 47 (02) :207-213
[37]   Heterogeneous radiological response to chemotherapy is associated with poor prognosis in advanced non-small-cell lung cancer [J].
Ryu, Woo Kyung ;
Kim, Jung Soo ;
Park, Mi Hwa ;
Lee, Minkyung ;
Kim, Hyun-Jung ;
Ryu, Jeong-Seon ;
Lim, Jun Hyeok .
THORACIC CANCER, 2021, 12 (24) :3333-3339
[38]   Differences in postoperative prognosis between early-stage lung adenocarcinoma and squamous cell carcinoma [J].
Izaki, Yu ;
Mimae, Takahiro ;
Kagimoto, Atsushi ;
Handa, Yoshinori ;
Tsutani, Yasuhiro ;
Miyata, Yoshihiro ;
Okada, Morihito ;
Takeshima, Yukio .
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2024, 54 (07) :813-821
[39]   Evaluation of advanced non-small-cell lung cancer (ANSCLC) chemotherapy in routine practice [J].
Jouveshomme, S ;
Hermant, P ;
Patte, D .
REVUE DES MALADIES RESPIRATOIRES, 2004, 21 (04) :719-726
[40]   Patients' preferences for chemotherapy in non-small-cell lung cancer: A systematic review [J].
Blinman, Prunella ;
Alam, Mahmood ;
Duric, Vlatka ;
McLachlan, Sue-Anne ;
Stockler, Martin R. .
LUNG CANCER, 2010, 69 (02) :141-147